Imdusiran - Arbutus Biopharma
Alternative Names: AB-729; ARB 270729Latest Information Update: 28 Jul 2025
At a glance
- Originator Arbutus Biopharma
- Developer Antios Therapeutics; Arbutus Biopharma; Assembly Biosciences
- Class Amides; Amino sugars; Antivirals; Drug conjugates; Small interfering RNA
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; Hepatitis B virus replication inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatitis B
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-B in Unknown (SC)
- 25 Jun 2025 Imdusiran is no longer licensed to Qilu Pharmaceuticals in Greater China
- 07 May 2025 Updated efficacy data from the phase IIa IM-PROVE II trial in Hepatitis B released by Arbutus Biopharma